Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term prognostic-factors. Found 21 abstracts

no pagination
Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA. Neuroendocrine Tumors Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2012 Jun;10(6):724-64.   PMCID: not NIH funded
McCarter MD, Antonescu CR, Ballman KV, Maki RG, Pisters PW, Demetri GD, Blanke CD, von Mehren M, Brennan MF, McCall L, Ota DM, DeMatteo RP, Amer Coll Surg Oncology Grp A. Microscopically Positive Margins for Primary Gastrointestinal Stromal Tumors: Analysis of Risk Factors and Tumor Recurrence. Journal of the American College of Surgeons. 2012 Jul;215(1):53-9.   PMCID: PMC3383609
von Mehren M, Benjamin RS, Bui MM, Casper ES, Conrad EU, DeLaney TF, Ganjoo KN, George S, Gonzalez R, Heslin MJ, Kane JM, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Shankar S, Van Tine BA, Wayne J, Sundar H, McMillian NR. Soft Tissue Sarcoma, Version 2.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Aug;10(8):951-60.   PMCID: not NIH funded
Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G. Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma. Journal of Clinical Oncology. 2012 Oct;30(28):3545-51.   PMCID: PMC3454772
Zaorsky NG, Li TY, Devarajan K, Horwitz EM, Buyyounouski MK. Assessment of the American Joint Committee on Cancer Staging (Sixth and Seventh Editions) for Clinically Localized Prostate Cancer Treated With External Beam Radiotherapy and Comparison With the National Comprehensive Cancer Network Risk-Stratification Method. Cancer. 2012 Nov;118(22):5535-43.   PMCID: PMC3410044
Hamilton CA, Miller A, Miller C, Krivak TC, Farley JH, Chernofsky MR, Stany MP, Rose GS, Markman M, Ozols RF, Armstrong DK, Maxwell GL. The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: A gynecologic oncology group study. Gynecologic Oncology. 2011 Sep;122(3):521-6.   PMCID: *
Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. Journal of Clinical Oncology. 2011 Mar;29(7):934-43.   PMCID: PMC3068065
McDonald MW, Lawson J, Garg MK, Quon H, Ridge JA, Saba N, Salama JK, Smith RV, Yeung AR, Yom SS, Beitler JJ, Expert Panel Radiation O. ACR APPROPRIATENESS CRITERIA (R) RETREATMENT OF RECURRENT HEAD AND NECK CANCER AFTER PRIOR DEFINITIVE RADIATION. International Journal of Radiation Oncology Biology Physics. 2011 Aug;80(5):1292-8.   PMCID: not NIH funded
Showalter TN, Winter KA, Berger AC, Regine WF, Abrams RA, Safran H, Hoffman JP, Benson AB, MacDonald JS, Willett CG. THE INFLUENCE OF TOTAL NODES EXAMINED, NUMBER OF POSITIVE NODES, AND LYMPH NODE RATIO ON SURVIVAL AFTER SURGICAL RESECTION AND ADJUVANT CHEMORADIATION FOR PANCREATIC CANCER: A SECONDARY ANALYSIS OF RTOG 9704. International Journal of Radiation Oncology Biology Physics. 2011 Dec;81(5):1328-35.   PMCID: PMC3038247
Chirieac LR, Flieder DB. High-Resolution Computed Tomography Screening for Lung Cancer Unexpected Findings and New Controversies Regarding Adenocarcinogenesis. Archives of pathology & laboratory medicine. 2010 Jan;134(1):41-8.   PMCID: not NIH funded
Reichardt P, Blay JY, von Mehren M. Towards global consensus in the treatment of gastrointestinal stromal tumor. Expert Review of Anticancer Therapy. 2010 Feb;10(2):221-32.   PMCID: PMC347555
Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Blute ML. Radiation Therapy After Radical Prostatectomy: Impact on Metastasis and Survival. Journal of Urology. 2009 Dec;182(6):2708-14.
Dupart JJ, Trent JC, Lee HY, Hess KR, Godwin AK, Taguchi T, Zhang W. Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro - art. no. 99. Molecular Cancer. 2009 Nov;8:99.   PMCID: PMC2780392
Figlin RA, de Souza P, McDermott D, Dutcher JP, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Boni J, Hudes G. Analysis of PTEN and HIF-1 alpha and Correlation With Efficacy in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus Versus Interferon-alpha. Cancer. 2009 Aug;115(16):3651-60.   PMCID: not NIH funded
Nebozhyn M, Loboda A, Kati L, Rook AH, Vonderheid EC, Lessin S, Berger C, Edelson R, Nichols C, Yousef M, Gudipati L, Shang ML, Showe MK, Showe LC. Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. BLOOD. 2006 Apr;107(8):3189-96.
Gorla SR, Hou N, Acharya S, Rademaker A, Khan S, Staradub V, Morrow M. A predictive model for the development of hormone-responsive breast cancer. Annals of Surgical Oncology. 2005 Jan;12(1):48-56.
Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. Journal of Clinical Oncology. 2005 Sep;23(25):6207-19.
Meyer JS, Alvarez C, Milikowski C, Olson N, Russo I, Russo J, Glass A, Zehnbauer BA, Lister K, Parwaresch RG. Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index. Modern Pathology. 2005 Aug;18(8):1067-78.
Travis WD, Garg K, Franklin WA, Wistuba, Sabloff B, Noguchi M, Kakinuma R, Zakowski M, Ginsberg M, Padera R, Jacobson F, Johnson BE, Hirsch F, Brambilla E, Flieder DB, Geisinger KR, Thunnisen F, Kerr K, Yankelevitz D, Franks TJ, Galvin JR, Henderson DW, Nicholson AG, Hasleton PS, Roggli V, Tsao MS, Cappuzzo F, Vazquez M. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinorna and bronchioloalveolar carcinoma. Journal of Clinical Oncology. 2005 May 10;23(14):3279-87.
von Mehren M, Watson JC. Gastrointestinal stromal tumors. Hematology-Oncology Clinics of North America. 2005 Jun;19(3):547-+.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term prognostic-factors

prognostic-factors imatinib mesylate chemotherapy therapy gist phase-ii trial surgical-management long-term survival kit ground-glass opacity randomized-trial carcinoma of-function mutations soft-tissue sarcomas antigen tyrosine kinase inhibitor dose imatinib expression thin-section ct atypical adenomatous hyperplasia trial Cytoreduction imatinib prediction adjuvant radiotherapy acute lymphoblastic-leukemia proliferation stromal tumor grading system retropubic prostatectomy progesterone-receptor status biochemical chemoprevention hormone-sensitive cancers estrogen receptor grade randomized phase-iii mtor inhibitor islet-cell carcinoma in-vivo prostate-specific antigen prostatectomy stem-cell expansion squamous-cell carcinoma guidelines Nodal ratio motexafin gadolinium gemcitabine residual disease progression antitumor-activity concurrent chemotherapy multivariate-analysis phase-ii aggressive surgery Network Microscopic residual growth risk zd1839 iressa adrenal-cortical carcinoma 2006 i ds-v24-p2396 2011 mmier rf-j clin oncol s-v29-p4103 prostatic neoplasms esophageal cancer bladder-cancer malignant lesions therapy-oncology-group flow-cytometry cancer histological grade apoptosis induction colorectal-cancer igfbp-3 interleukin-12 therapy breast neoplasms intraperitoneal cisplatin lung-cancer curative resection phase-iii trial salvage surgery European Society of Medical Oncology peripheral adenocarcinoma staging prostate cancer-radiotherapy-American Joint Committee on Cancer-National Comprehensive Cancer Network cancer patients carboplatin oncology-group mitotic count doubling time KIT ductal adenocarcinoma breast-cancer cells gleason score plus irinotecan pathway radiolabeled somatostatin analog metastatic Bloom-Richardson estrogen-receptor hepatic arterial chemoembolization pancreaticoduodenectomy 1987 grath pc-annals of surgery-v206-p706 metastatic carcinoid-tumors surgery positive cancers gastrointestinal stromal tumors sezary-syndrome adrenocortical tumors cell kinetics randomized clinical-trial high-resolution ct radiation-therapy National Comprehensive Cancer Reirradiation progression-free survival nucleotide polymorphism analysis trail-induced apoptosis tyrosine kinase stereotactic radiosurgery inhibitor fibromatosis standard beta receptor Salvage c-kit sunitinib pulmonary adenocarcinoma gastroenteropancreatic tumors epithelial-cells mammalian target cell lung-cancer wedge resection growth-factor transitional-cell carcinoma mycosis-fungoides 2nd-line treatment t-plastin antigen presentation thymidine labeling index base-line men postmenopausal women epidemiologic characteristics somatostatin analog bromodeoxyuridine iowa womens health desmoid tumor bronchioloalveolar carcinoma interstitial-cells chronic myeloid-leukemia
Last updated on Friday, December 06, 2019